

SKIN VACCINATION SUMMIT 2020

17-19 March 2020, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR SVS 2020

Recognition of the skin by vaccinologists as an ideal anatomical target has gathered momentum in the past decade. The premise that the dense population of APCs can be targeted, stimulated and loaded with antigens to induce robust immune responses and result in more efficacious vaccines has stimulated many efforts to understand skin physiology, the skin immune system antigen presenting cells, effector responses and modes of immune stimulation and delivery formats. The field is ripe to have broad interchange on relevant related disciplines to focus both research and development efforts on more effective and informative directions. With several products in late stage development and a newly licensed delivery device, a timely multi disciplinary interchange is greatly needed to help set the stage for progress that can lead to capitalizing on the immunopotency of the skin to bring about better human health.

The fifth SKIN VACCINATION SUMMIT – SVS 2020 will again offer an international forum for researchers, both academic and industrial, plus regulators and skin delivery technologists to meet and discuss the current developments and future direction and technology trends in the dynamic field of skin mediated vaccination.

The SVS 2020 meeting will comprise keynote presentations and special sessions and in addition the SVS 2020 organisers invite oral and poster abstract submissions to be considered for inclusion in the meeting schedule.

SCIENTIFIC ADVISORY PANEL

Mark Kendall (*University of Queensland, Australia*)

Richard Compans (*Emory University, Atlanta, Georgia, USA*)

Behazine Combadiere (*INSERM, Paris, France*)

Darin Zehrung (*PATH, Seattle, Washington, USA*)

Yotam Levin (*NanoPass Technologies Ltd, Rehovot, Israel*)

Mark Prausnitz (*Georgia Institute of Technology, Atlanta, USA*)

Ryan Donnelly (*Queen's University Belfast, Northern Ireland, UK*)

Terry L. Bowersock (*Zoetis Inc., Kalamazoo, Michigan, USA*)

Michael Royals (*Independent Consultant, Denver, Colorado, USA*)

Derek O'Hagan (*GSK, Cambridge, Massachusetts, USA*)

Steve Reed (*IDRI, Seattle, Washington, USA*)

Anne Moore (*University of Cork, Cork, Ireland*)

Marcel B.M. Teunissen (*University of Amsterdam, Amsterdam, The Netherlands*)

Izzy Tsals (*SID Technologies LLC, Newtown, Pennsylvania, USA*)

Laurent-Dominique Piveteau (*Debiotech SA, Lausanne, Switzerland*)

Bobby Singh (*Corium International, Menlo Park, California, USA*)

Cees W.J. Oomens (*Eindhoven University of Technology, Eindhoven, The Netherlands*)

Claus-Michael Lehr (*Helmholtz Center for Infection Research (HZI), Saarland University, Saarbrücken, Germany*)

Esther de Jong (*University of Amsterdam, Amsterdam, The Netherlands*)







Ferry A. Ossendorp (*Leiden University Medical Center, Leiden, The Netherlands*)

Maria G. Isagulians (*Karolinska Institute, Stockholm, Sweden*)

Markus Clemenz (*Verapido Medical GmbH, Villingen-Schwenningen, Germany*)

SKIN VACCINATION SUMMIT 2020 SCOPE

- **Layers and cells** – considerable new data and debate on the skin APCs, their roles in immunity and their relevance to antigen presentation – Special session on Dendritic Cells.
- **Principles of Stratum Corneum Disruption** – to immunize one has to access the living skin, so there are many techniques under development to do this – physics and physiology as it related to SC disruption/penetration.
- **Techniques for SC Disruption/Penetration: Methods and Madness** (microneedles, microprojections, dissolvable needle approaches, ID, Patches – size) – Use, cost and commercialisation.
- **Techniques for ID injection** – New methods and field experience with novel skin vaccines dermal delivery of DNA vaccines.
- **Skin vaccination** – mechanistic interpretations (antigen trafficking across skin) – Reactivity issues (adjuvants and repeated dosing).
- **Animals and in vitro models for skin delivery** – active field, most everyone working in the field needs to upgrade their approach – toxicology.
- **Clinical Evidence for the immunological advantage of skin targeting** – Clinical data only, many studies and investigators... ID mainly but several techniques.
- **Immunological Rationale for skin targeting** – effector results, T cells, humoral and mucosal antibodies – preclinical evidence for the immunological advantage of skin targeting – local reactions.
- **Adjuvants for skin targeting** – there are many cancer trials using skin and delivery adjuvants to the skin – there are many adjuvants in development to target skin – tox/reactogenicity requirements for skin targeting.
- **Public health aspects of skin immunization** – improving access to vaccines – stabilization technologies to avoid the cold chain – prospects for self-administered vaccines – issues for mass vaccination.
- **Prophylactic vs therapeutic vaccines and skin delivery.**
- **Size of patches or delivery systems** – multivalent versus monovalent vaccine applications and live versus inactivated vaccines.
- **Formulation matters** • **Immune medium (cytokine production by DCs, adipocytes, fibroblasts etc)** • **Immune suppression of skin constituents** • **In vitro skin models** • **Regulatory planning for ID vaccines.**



Abstract Submissions

The SVS 2020 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during SVS 2020. The one page abstract should contain sufficient information for the Scientific Advisory Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (SVS 2020 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: **Friday 4th October 2019**. Authors will be informed of the status of their contribution(s) in November 2019.

Closing date for submissions intended for poster presentation: **Friday 21st February 2020**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration.

Participation

All non-invited speakers will be expected to register as delegates to SVS 2020. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at SVS 2020. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- I wish to be placed on the mailing list to receive further information on SVS 2020
- I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of abstract:

.....

Intended session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

.....

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please Type/Print):

- My organisation is interested in sponsoring SVS 2020 Please send me details of exhibition/delegate pack insert service

REQUEST DETAILS OF FUTURE EVENTS

- MODERN VACCINES ADJUVANTS & DELIVERY SYSTEMS** – 9-11 September 2019, Bern, Switzerland
- VACCINES FOR ENTERIC DISEASES** – 16-18 October 2019, Lausanne, Switzerland
- UNIVERSAL INFLUENZA VACCINES** – 29-30 April – 1 May 2020, Oxford, UK
- VIRUS-LIKE PARTICLE & NANO-PARTICLE VACCINES** – 15-17 June 2020, Riga, Latvia

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, SVS 2020, MEETINGS MANAGEMENT

Danehurst, Nore Lane, Hascombe, Godalming, Surrey GU8 4JT, United Kingdom

Telephone: +44 (0)1483 427770 E-mail: jherriot@meetingsmgmt.u-net.com Website: www.meetingsmanagement.com/atdc_2019